Impaired glucose metabolism in irritable bowel syndrome: personalised low-glycaemic diet as potential therapeutic target
Hyperglycaemia could drive intestinal barrier dysfunction. These findings establish a compelling rationale for targeting glucose metabolism in IBS. Therefore, PN, targeting individual glycaemic responses, may represent a paradigm shift in functional GI disorder management, offering both mechanistic rationale and practical advantages over current dietary interventions. Our findings suggest that patients with IBS exhibit impaired glucose metabolism and that PLGD can achieve therapeutic benefits comparable to established treatments. The mechanistic insights provided by Gilliam-Vigh et al. underscore the role of metabolic–immune interactions, combined with evidence that supports targeted interventions.
Preview
Rights
Use and reproduction:
Please note that individual components of the publication may be subject to other licensing or copyright conditions.